Table 2.
Comparison of efficacy of RT-PD1 group with PD1 group based on tumor response before and after PSM.
| Variables | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n = 172) | RT + PD1 (n = 95) | PD1 (n = 77) | P value | Overall (n = 142) | RT + PD1 (n = 71) | PD1 (n = 71) | P value | |
| Tumor response, n (%) | <0.001 | 0.003 | ||||||
| CR | 5 (2.9) | 4 (4.2) | 1 (1.3) | 3 (2.1) | 2 (2.8) | 1 (1.4) | ||
| PR | 51 (29.7) | 36 (37.9) | 15 (19.5) | 40 (28.2) | 27 (38.0) | 13 (18.3) | ||
| SD | 34 (19.8) | 25 (26.3) | 9 (11.7) | 23 (16.2) | 15 (21.1) | 8 (11.3) | ||
| Progressive disease | 82 (47.7) | 30 (31.6) | 52 (67.5) | 76 (53.5) | 27 (38) | 49 (69) | ||
| Response rate (%) | ||||||||
| ORR | 32.6 | 42.1 | 20.7 | 0.003 | 30.3 | 40.8 | 19.7 | 0.006 |
| DCR | 52.3 | 68.4 | 32.5 | <0.001 | 46.5 | 62.0 | 31.0 | <0.001 |
| Median time to achieve best response (months) | 3.1 | 2.8 | 3.4 | 0.065 | 3.0 | 2.8 | 3.4 | 0.113 |
CR: Complete response; DCR: Disease control rate; ORR: Objective response rate; PD1: Anti-programmed death receptor-1 inhibitor; PR: Partial response; PSM: Propensity score matching; RT: Radiotherapy; SD: Stable disease.